Specifically, BRAF V600E-mutant CRC has been linked to a distinct immune microenvironment characterized by increased infiltration of immunosuppressive cells, including M2 TAMs, and a reduced response to immunotherapy [85]. This evidence concerns the gene BRAF and colorectal carcinoma.